SARS-CoV-2 is predominantly a respiratory disease that spreads primarily through direct contact (droplets, person to person). However, gastrointestinal (GI) symptoms such as vomiting, nausea, diarrhoea, and abdominal pain are becoming more often recognised as COVID-19 symptoms. Other symptoms of COVID-19, such as dysgeusia and anosmia, have also become more well-known. Studies have also found that these GI symptoms are frequently an early manifestation of Covid-19 and hence a strong predictor of the virus's emergence. There are still many unanswered questions and challenges, such as the relevance of virus detection in asymptomatic subjects' stool/rectal swabs, whether ACE2 is a direct mediator for SARS-CoV-2 entry into the GI tract, and how the virus might survive passage through the digestive system's extreme pH environment. As a result, it's critical to see Covid-19 as more than a respiratory disease and to identify approaches to manage the disease's gastrointestinal component.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Complex endoscopy in pediatrics: Optimizing care
Monique Barakat, Stanford University School of Medicine, United States
Title : Use of indocyanine green fluorescence imaging in the extrahepatic biliary tract surgery
Orestis Ioannidis, Aristotle University of Thessaloniki, Greece
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States
Title : Efficacy of sertraline on the symptoms and quality of life in patients with irritable bowel syndrome: A single-blinded and parallel designed randomized controlled trial
Sara Seifouri, St. Thomas NHS Foundation Trust, United Kingdom